Whitehawk (WHWK) CFO Giacobello Receives 236,952-Share Award

What Happened
Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics (WHWK), received two derivative equity awards on 2026-09-15, each for 118,476 shares, for a total of 236,952 shares. Both awards are reported at $0.00 (no cash paid at grant). One award is described with an option-style vesting schedule and the other is reported as restricted stock units (RSUs) that convert to common shares if vesting conditions are met.

Key Details

• Transaction date: 2026-09-15 (reported in an amended Form 4 filed 2026-09-18). The filing is an amendment correcting vesting terms from the original Form 4.
• Awards: two derivative acquisitions of 118,476 shares each (total 236,952 shares) at $0.00 per share.
• Vesting: Vesting Commencement Date is Sept 15, 2026. Footnote details:
  • F1 (option-style award): subject to continued service; 25% vests on the one-year anniversary, then 1/48th per month thereafter (fully vested after 4 years).
  • F2 (RSU): each RSU equals the right to one share.
  • F3 (correction): for the reported RSU award, 100% of shares will vest on the one-year anniversary of the Vesting Commencement Date (correcting an earlier, incorrect vesting schedule).
• Shares owned after the transaction: not specified in the provided excerpt.
• Filing status: this is an amended Form 4 correcting vesting terms from the originally filed report.

Context

• These are grants (A = Award) and are contingent on continued service; they do not represent an immediate cash purchase or sale.
• RSUs and option-style awards reported at $0.00 are common for executive compensation and signal future potential share issuance if vesting conditions are met; they do not by themselves indicate immediate buying or selling activity.
• Because this filing is an amendment, the primary significance is the corrected vesting schedule (not a change in share count).